Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies Including Stargardt Disease

Ocugen11/20 13:00

Ocugen Reports Positive Data for OCU400, OCU410

Seeking Alpha11/19 23:10

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen11/19 13:00

Ocugen Is Maintained at Buy by Chardan Capital

Dow Jones11/19 06:13

“减肥双雄”领衔医药股大跌，特朗普的新卫生部长反对疫苗和减肥药

wallstreetcn11/17 20:00

Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates

Zacks 11/15 04:50